Literature DB >> 21964066

The p53-p21WAF1 checkpoint pathway plays a protective role in preventing DNA rereplication induced by abrogation of FOXF1 function.

Pang-Kuo Lo1, Ji Shin Lee, Saraswati Sukumar.   

Abstract

We previously identified FOXF1 as a potential tumor suppressor gene with an essential role in preventing DNA rereplication to maintain genomic stability, which is frequently inactivated in breast cancer through the epigenetic mechanism. Here we further addressed the role of the p53-p21(WAF1) checkpoint pathway in DNA rereplication induced by silencing of FOXF1. Knockdown of FOXF1 by small interference RNA (siRNA) rendered colorectal p53-null and p21(WAF1)-null HCT116 cancer cells more susceptible to rereplication and apoptosis than the wild-type parental cells. In parental HCT116 cells with a functional p53 checkpoint, the p53-p21(WAF1) checkpoint pathway was activated upon FOXF1 knockdown, which was concurrent with suppression of the CDK2-Rb cascade and induction of G(1) arrest. In contrast, these events were not observed in FOXF1-depleted HCT116-p53-/- and HCT116-p21-/- cells, indicating that the p53-dependent checkpoint function is vital for inhibiting CDK2 to induce G(1) arrest and protect cells from rereplication. The pharmacologic inhibitor (caffeine) of ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3 related (ATR) protein kinases abolished activation of the p53-p21(WAF1) pathway upon FOXF1 knockdown, suggesting that suppression of FOXF1 function triggered the ATM/ATR-mediated DNA damage response. Cosilencing of p53 by siRNA synergistically enhanced the effect of FOXF1 depletion on the stimulation of DNA rereplication and apoptosis in wild-type HCT116. Finally, we show that FOXF1 expression is predominantly silenced in breast and colorectal cancer cell lines with inactive p53. Our study demonstrated that the p53-p21(WAF1) checkpoint pathway is an intrinsically protective mechanism to prevent DNA rereplication induced by silencing of FOXF1.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21964066      PMCID: PMC3205208          DOI: 10.1016/j.cellsig.2011.09.017

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  40 in total

1.  p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor.

Authors:  J Yun; H D Chae; H E Choy; J Chung; H S Yoo; M H Han; D Y Shin
Journal:  J Biol Chem       Date:  1999-10-15       Impact factor: 5.157

Review 2.  Stressing the role of FoxO proteins in lifespan and disease.

Authors:  Armando van der Horst; Boudewijn M T Burgering
Journal:  Nat Rev Mol Cell Biol       Date:  2007-06       Impact factor: 94.444

3.  Negative regulation of Wee1 expression and Cdc2 phosphorylation during p53-mediated growth arrest and apoptosis.

Authors:  S D Leach; C D Scatena; C J Keefer; H A Goodman; S Y Song; L Yang; J A Pietenpol
Journal:  Cancer Res       Date:  1998-08-01       Impact factor: 12.701

4.  How p53 binds DNA as a tetramer.

Authors:  K G McLure; P W Lee
Journal:  EMBO J       Date:  1998-06-15       Impact factor: 11.598

5.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage.

Authors:  F Bunz; A Dutriaux; C Lengauer; T Waldman; S Zhou; J P Brown; J M Sedivy; K W Kinzler; B Vogelstein
Journal:  Science       Date:  1998-11-20       Impact factor: 47.728

6.  Hepatocyte nuclear factor 3/fork head or "winged helix" proteins: a family of transcription factors of diverse biologic function.

Authors:  E Lai; K L Clark; S K Burley; J E Darnell
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

7.  Forkhead box F1 is essential for migration of mesenchymal cells and directly induces integrin-beta3 expression.

Authors:  Dmitriy Malin; Il-Man Kim; Evan Boetticher; Tanya V Kalin; Sneha Ramakrishna; Lucille Meliton; Vladimir Ustiyan; Xiangdong Zhu; Vladimir V Kalinichenko
Journal:  Mol Cell Biol       Date:  2007-01-29       Impact factor: 4.272

8.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

Authors:  Richard M Neve; Koei Chin; Jane Fridlyand; Jennifer Yeh; Frederick L Baehner; Tea Fevr; Laura Clark; Nora Bayani; Jean-Philippe Coppe; Frances Tong; Terry Speed; Paul T Spellman; Sandy DeVries; Anna Lapuk; Nick J Wang; Wen-Lin Kuo; Jackie L Stilwell; Daniel Pinkel; Donna G Albertson; Frederic M Waldman; Frank McCormick; Robert B Dickson; Michael D Johnson; Marc Lippman; Stephen Ethier; Adi Gazdar; Joe W Gray
Journal:  Cancer Cell       Date:  2006-12       Impact factor: 31.743

9.  Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.

Authors:  Klaus W Wagner; Elizabeth A Punnoose; Thomas Januario; David A Lawrence; Robert M Pitti; Kate Lancaster; Dori Lee; Melissa von Goetz; Sharon Fong Yee; Klara Totpal; Ling Huw; Viswanatham Katta; Guy Cavet; Sarah G Hymowitz; Lukas Amler; Avi Ashkenazi
Journal:  Nat Med       Date:  2007-09-02       Impact factor: 53.440

10.  Deregulated replication licensing causes DNA fragmentation consistent with head-to-tail fork collision.

Authors:  Iain F Davidson; Anatoliy Li; J Julian Blow
Journal:  Mol Cell       Date:  2006-11-03       Impact factor: 17.970

View more
  16 in total

1.  The expanding role of the Ehmt2/G9a complex in neurodevelopment.

Authors:  Steven J Deimling; Jonathan B Olsen; Vincent Tropepe
Journal:  Neurogenesis (Austin)       Date:  2017-05-02

2.  The controversial role of forkhead box F2 (FOXF2) transcription factor in breast cancer.

Authors:  Pang-Kuo Lo
Journal:  PRAS Open       Date:  2017-07-22

3.  Prognostic impact of FOXF1 polymorphisms in gastric cancer patients.

Authors:  S Matsusaka; A H Wu; S Cao; D L Hanna; K Chin; D Yang; W Zhang; Y Ning; S Stintzing; A Sebio; Y Sunakawa; S Stremitzer; S Yamauchi; S Okazaki; M D Berger; A Parekh; Y Miyamoto; N Mizunuma; H-J Lenz
Journal:  Pharmacogenomics J       Date:  2017-04-11       Impact factor: 3.550

4.  Cytoplasmic mislocalization of overexpressed FOXF1 is associated with the malignancy and metastasis of colorectal adenocarcinomas.

Authors:  Pang-Kuo Lo; Ji Shin Lee; Hexin Chen; David Reisman; Franklin G Berger; Saraswati Sukumar
Journal:  Exp Mol Pathol       Date:  2012-10-24       Impact factor: 3.362

5.  The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression.

Authors:  Pang-Kuo Lo; Ji Shin Lee; Xiaohui Liang; Saraswati Sukumar
Journal:  Cell Signal       Date:  2016-07-01       Impact factor: 4.315

6.  FOXF1 mediates mesenchymal stem cell fusion-induced reprogramming of lung cancer cells.

Authors:  Hong-Jian Wei; Jac A Nickoloff; Wei-Hong Chen; Hen-Yu Liu; Wen-Cheng Lo; Ya-Ting Chang; Pan-Chyr Yang; Cheng-Wen Wu; David F Williams; Juri G Gelovani; Win-Ping Deng
Journal:  Oncotarget       Date:  2014-10-15

7.  Identical effects of VEGF and serum-deprivation on phenotype and function of adipose-derived stromal cells from healthy donors and patients with ischemic heart disease.

Authors:  Bjarke Follin; Josefine Tratwal; Mandana Haack-Sørensen; Jens Jørgen Elberg; Jens Kastrup; Annette Ekblond
Journal:  J Transl Med       Date:  2013-09-18       Impact factor: 5.531

8.  EZH2 silencing with RNA interference induces G2/M arrest in human lung cancer cells in vitro.

Authors:  Hui Xia; Wen Zhang; Yingjie Li; Nannan Guo; Changhai Yu
Journal:  Biomed Res Int       Date:  2014-03-18       Impact factor: 3.411

9.  Thymidylate synthase expression and p21(WAF1)/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy.

Authors:  Violetta Sulzyc-Bielicka; Pawel Domagala; Dariusz Bielicki; Krzysztof Safranow; Wenancjusz Domagala
Journal:  Cell Oncol (Dordr)       Date:  2013-11-26       Impact factor: 6.730

10.  Decreased FOXF1 promotes hepatocellular carcinoma tumorigenesis, invasion, and stemness and is associated with poor clinical outcome.

Authors:  Zhen-Guo Zhao; De-Qiang Wang; De-Fei Hu; You-Sheng Li; Shuang-Hai Liu
Journal:  Onco Targets Ther       Date:  2016-03-23       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.